Statins in hospitalized COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(6)

Published: May 31, 2023

Abstract This systematic review and meta‐analysis aimed to determine the efficacy of statins in hospitalized patients with coronavirus disease‐2019 (COVID‐19). A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov , without language restrictions. Randomized controlled trials (RCTs) on treatment COVID‐19 statins, compared placebo or standard care, were reviewed. Seven RCTs (enrolling 1830 participants) met inclusion criteria. There no statistically significant difference all‐cause mortality (risk ratio [RR]: 0.92, 95% confidence interval [CI]: 0.75–1.13), length hospital stay (weighted mean difference: −0.21 days, CI: −1.01 0.59 days), intensive care unit (ICU) admission (RR: 1.84, 0.45–7.55), mechanical ventilation 1.09, 0.70–1.70) between two groups. Statins failed reduce mortality, ICU admission, ventilation, COVID‐19. probably should not be used routinely patients.

Language: Английский

---

Anakinra was not associated with lower mortality in hospitalised COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials

Reviews in Medical Virology, Journal Year: 2023, Volume and Issue: 33(2)

Published: Jan. 4, 2023

The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This meta-analysis aimed determine efficacy of anakinra on mortality in patients with COVID-19. A systematic search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Randomized controlled trials treatment COVID-19 anakinra, compared placebo or blank, were reviewed. Studies pooled risk ratios (RRs), 95% confidence intervals (CIs). Five (enrolling 1859 participants) met inclusion criteria. There no statistically significant difference 14-day (RR 0.78, CI 0.43-1.39; P = 0.40), 28-day 1.06, 0.89-1.26; 0.51), 90-day 1.01, 0.73-1.39; 0.97) between two groups. Sensitivity analyses further confirmed these results. Anakinra not associated reduced hospitalised probably should be used routinely patients.

Language: Английский

---

Cost‐effectiveness of plasmapheresis and hemoperfusion in COVID‐19 survivors: A six‐month follow‐up analysis after hospital discharge

Therapeutic Apheresis and Dialysis, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 14, 2025

Abstract Introduction To evaluate the short‐ and long‐term clinical financial outcomes of apheresis in COVID‐19 survivors after hospital discharge. Methods Intensive care unit‐discharged patients were followed for 6 months. Vital signs, laboratory markers, quality life, direct medical costs analyzed to calculate incremental cost‐effectiveness ratios (ICER) plot planes acceptability curves. Results A total 68 (45 control, 18 plasmapheresis, 5 hemoperfusion) included. ICERs plasmapheresis hemoperfusion at discharge $867.58 $198.89 per quality‐adjusted life years (QALY) gained, respectively. Respiration blood pressure improved significantly The improvements oxygenation markers groups lower than controls (8.56 ± 10.31 11.75 16.88 vs. 11.37 7.28 percent SpO 2 , 11.15 21.15 11.05 24.95 16.03 5.61 mm Hg PaO respectively) However, respiratory rate corresponded $1034.77 $269.94 hemoperfusion, increasing mean arterial $24.83 $30.94 Hg, was more cost‐effective serum calcium levels ($1649.35 mg/dL). At 1‐month post‐discharge, both treatments showed worse compared controls. months, ICER ($1884.95) exceeded willingness‐to‐pay threshold. months $112.83 rehospitalization day avoided, while remained less effective Conclusion While some outcomes, their high limited suggest that these interventions may not be economically justified treating patients. Careful evaluation is needed when considering use practice.

Language: Английский

---

Therapeutic plasma exchange accelerates immune cell recovery in severe COVID-19

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 17, 2025

Immunological disturbances (anti-type I IFN auto-antibody production, cytokine storm, lymphopenia, T-cell hyperactivation and exhaustion) are responsible for disease exacerbation during severe COVID-19 infections. In this study, we set up a prospective, randomised clinical trial (ClinicalTrials.gov ID: NCT04751643) performed therapeutic plasma exchange (TPE) in patients order to decrease excess cytokines auto-antibodies assess whether adding TPE the standard treatment (ST, including corticosteroids plus high-flow rate oxygen) could help restore immune parameters limit progression of acute respiratory distress syndrome (ARDS). As expected, performing decreased amount anti-type improved elimination or limited production certain inflammatory mediators (IL-18, IL-7, CCL2, CCL3, etc.) circulating blood patients, compared ST controls. Interestingly, while did not influence changes ARDS throughout protocol, it proved more effective than reversing preventing reducing exhaustion, notably fraction who had an early favourable outcome. also restored appropriate numbers CD4+ CD8+ memory populations increased number virus-specific T cells these patients. Our results therefore indicate that addition sessions accelerates cell recovery contributes development antiviral responses some with disease.

Language: Английский

---

Benefits of melatonin on mortality in severe-to-critical COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials

Clinics, Journal Year: 2025, Volume and Issue: 80, P. 100638 - 100638

Published: Jan. 1, 2025

Language: Английский

---

Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review

Journal of Blood Medicine, Journal Year: 2023, Volume and Issue: Volume 14, P. 159 - 187

Published: Feb. 1, 2023

Abstract: Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, 6,572,800 mortalities and, a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms pulmonary and infections death may be SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, anticoagulants proposed potential medicines to cure COVID-19 affected patients. Among these initial convalescent plasma (CCP), which retrieved from recovered patients used passive immune therapy, in antibodies cured were given infected prevent illness. Such treatment has yielded the best results earlier preventative early stages Convalescent (CP) is first available when infectious disease initially appears, although few randomized controlled trials (RCTs) conducted evaluate its effectiveness. historical record suggests benefit for other infections, coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) Middle Eastern Syndrome (MERS), though analysis such research constrained some non-randomized experiments (NREs). Rigorous studies CP are made more demanding following immediacy epidemics, use restrict ability utilize it clinical testing, non-homogenous nature product, highly decentralized manufacturing process; constraints capacity measure biologic function, ultimate availability substitute therapies, purified globulins, monoclonal antibodies. Though, still not clear how effectively CCP works among hospitalized current review tries focus efficiency usage scenarios identifying existing benefits implementation during assist future preventions. Keywords: plasma, effectiveness, CCP, disease-2019, SARA-CoV-2, distress syndrome-coronavirus-2, era, literature

Language: Английский

---

Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: July 6, 2023

Nowadays, people have relaxed their vigilance against COVID-19 due to its declining infection numbers and attenuated virulence. However, still needs be concern emerging variants, the relaxation of restrictions as well breakthrough infections. During period infection, imbalanced hyper-responsive immune system plays a critical role in pathogenesis. Macrophage Activation Syndrome (MAS) is fatal complication disease, which caused by excessive activation proliferation macrophages cytotoxic T cells (CTL). COVID-19-related hyperinflammation shares common clinical features with above MAS symptoms, such hypercytokinemia, hyperferritinemia, coagulopathy. In MAS, exhaustion or defective anti-viral responses leads inadequate cytolytic capacity CTL contributes prolonged interaction between CTL, APCs macrophages. It possible that same process also occurred patients, further led cytokine storm confined lungs. associated poor prognosis severe patients multiple organ failure even death. The main difference pneumonia mainly specific damage lung, while easy develop into systemic. attractive therapeutic approach prevent includes antiviral, antibiotics, convalescent plasma (CP) therapy hemadsorption, extensive immunosuppressive agents, cytokine-targeted therapies. Here, we discuss approaches mentioned two diseases. And found treatment effect different.

Language: Английский

---

Selexipag in Patients With Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Current Problems in Cardiology, Journal Year: 2022, Volume and Issue: 48(2), P. 101466 - 101466

Published: Oct. 23, 2022

Language: Английский

---

Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta‐analysis

Clinical Cardiology, Journal Year: 2022, Volume and Issue: 45(10), P. 995 - 1001

Published: Aug. 2, 2022

Abstract Considering the prevalence of dyspnea in acute heart failure (AHF), its reduction is important to both patients and caregivers. This meta‐analysis was performed determine efficacy safety tolvaptan on early relief with AHF. A systematic search made PubMed, Embase, Web Science, Cochrane Library, clinicaltrials.gov , without language restrictions. Randomized controlled trials (RCTs) treatment AHF tolvaptan, compared placebo or blank, were reviewed. Studies pooled relative risk (RR), 95% confidence interval (CI). Five RCTs (enrolling 4857 participants) met inclusion criteria. Tolvaptan presented significant effects 12 h (RR: 1.98; CI: 1.24−3.15; p = .004), 24 h/day 1 1.15; 1.07−1.24; .0003), 48 1.20; 1.06−1.36; 72 1.18; 1.02−1.37; .03). No increase noticed incidence worsening renal function group 1.10; 0.87−1.39; .43). significantly improved patient‐assessed persistently

Language: Английский

---

Benefits of ozone on mortality in patients with COVID-19: A systematic review and meta-analysis

Complementary Therapies in Medicine, Journal Year: 2022, Volume and Issue: 72, P. 102907 - 102907

Published: Dec. 10, 2022

The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. Ozone therapy has long been used in treatment of a variety infectious diseases, probably through its antioxidant properties supply oxygen hypoxic tissues. This systematic review meta-analysis aimed determine efficacy ozone on mortality patients with COVID-19.A search was made PubMed, Embase, Cochrane Library, clinicaltrials.gov, without language restrictions. Prospective controlled trials COVID-19 ozone, compared placebo or blank, were reviewed. Studies pooled risk ratios (RRs) weighted mean differences (WMDs), 95% confidence intervals (CIs).Eight (enrolling 371 participants) met inclusion criteria. showed significant effects (RR 0.38, CI 0.17-0.85; P = 0.02), length hospital stay (WMD -1.63 days, -3.05 -0.22 days; polymerase chain reaction (PCR) positivity 0.07, 0.01-0.34; 0.001).Ozone significantly reduced mortality, PCR positivity, hospitalized COVID-19. should be considered for patients.

Language: Английский

---